318 - Activity of Omadacycline Against 35,000 Bacterial Clinical Isolates and Resistant Organism Subsets from Patients in the United States (2019–2023)

Friday, October 18, 2024

12:25 PM – 12:30 PM US PT

Location: Halls JK - Arena 1

Rapid Fire Presenter(s)

MH

Michael D. Huband, BS

Associate Director
Element
North Liberty, IA, United States

Co-Author(s)

KF

Kelley A. Fedler, BS

Surveillance Manager
Element
North Liberty, Iowa, United States
Kelly Wright, PharmD, BCPS

Director, Medical Science and Publications
Paratek Pharmaceuticals, Inc.
king of Prussia, Pennsylvania, United States
Rodrigo E. Mendes, PhD (he/him/his)

Director
Element, Iowa City (JMI Laboratories)
North Liberty, IA, United States
MC

Mariana Castanheira, PhD

CSO
Element
North Liberty, IA, United States

Disclosure(s):

Michael D. Huband, BS: Paratek Pharmaceuticals: Advisor/Consultant, Grant/Research Support

Kelley A. Fedler, BS: Paratek Pharmaceuticals: Grant/Research Support

Kelly Wright, PharmD, BCPS: Paratek Pharmaceuticals: Employee

Rodrigo E. Mendes, PhD: JMI: RM is an employee of JMI. JMI was contracted by and received financial support from GSK to conduct gepotidac; Paratek Pharmaceuticals: Advisor/Consultant, Grant/Research Support

Mariana Castanheira, PhD: Paratek Pharmaceuticals: Advisor/Consultant, Grant/Research Support